Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences

Dow Jones

05/09

By Kelly Cloonan

Kestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday.

First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours.

Inhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 08, 2026 18:40 ET (22:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2634498342"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634498342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634498342?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634498342","market":"hk","top_or_hot":-1,"title":"Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KG\">Kestrel</a> Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n</p>\n<p>\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 06:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KG\">Kestrel</a> Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n</p>\n<p>\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634498342","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634498342","pubTimestamp":1778280000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday.First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours.Inhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KG":"Kestrel","INBX":"Inhibrx Biosciences","BK4019":"再保险"},"translate_title":"值得关注的股票：Kestrel Group、First Tracks Biotherapeutics、Inhibrx Biosciences","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KG":1.5,"INBX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\nKestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n\n\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n\n\nInhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 18:40 ET (22:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}